Cognito Therapeutics to Present Phase 2 OVERTURE Study Open-Label Extension Data Showing Safety and Durability of Treatment Benefits Over 18 Months at CTAD 2023

– Data will highlight durability of treatment effect and significant impact on slowing disease progression.

– No treatment-related serious adverse events (SAEs) or incidents of amyloid-related imaging abnormalities (ARIA) over the course of 18 months.

– Findings from cerebrospinal fluid (CSF) proteomic biomarkers align with unique mechanism of action responsible for decreased rate of brain atrophy, in line with preservation of cognitive function.

CAMBRIDGE, Mass.–(BUSINESS WIRE)–#CTAD2023—Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, announced today it has been selected to present clinical data as a late-breaker abstract from its proprietary investigational disease-modifying therapy in patients with Alzheimer’s Disease, at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference taking place in Boston and online, October 24-27, 2023.

“We are thrilled to present our Phase 2 study open-label extension results at CTAD 2023, demonstrating that our novel disease modifying therapeutic approach had a durable treatment effect over an 18-month period while uniquely reducing brain atrophy with no treatment limiting significant adverse events or ARIA, in patients with Alzheimer’s Disease,” said Brent Vaughan, CEO of Cognito Therapeutics. “Our Phase 2 OLE data highlights the safety, high adherence and efficacy of our approach in significantly decelerating disease progression, effectively preserving both brain function and volume in Alzheimer’s patients.”

“We firmly believe that the preservation of brain gray and white matter is an important Alzheimer’s Disease treatment objective and shows a strong correlation with patient outcomes, with far-reaching implications across a variety of neurological disorders,” said Ralph Kern MD MHSc, Chief Medical Officer, Cognito Therapeutics. “Once approved, our DMT can be seamlessly integrated as a home-based treatment into the lives of patients and caregivers, as a novel precision neurology therapy.”

Details of the poster presentations are below:

Poster Title: OVERTURE open-label extension data confirm safety, adherence, and durability of treatment benefits over 18 months

Poster Number: LP026

Presenter: Ralph Kern, MD, MHSc, Chief Medical Officer, Cognito Therapeutics

Poster Title: Biomarker responses to gamma sensory stimulation in Alzheimer’s disease patients assessed in HOPE clinical trial

Poster Number: P072

Presenter: Mihaly Hajos, PhD, Chief Scientific Officer, Cognito Therapeutics

Poster Title: CSF proteomic insights into the mechanism of action of gamma sensory stimulation in Alzheimer’s disease

Poster Number: P080

Presenter: Kiran Pandey, CEO, Emtherapro, Inc

Poster Title: High Adherence and Tolerability of a Sensory Stimulation System in a 6-Month Sham-Controlled Clinical Trial in Alzheimer’s Disease

Poster Number: P041

Presenter: Chandran Seshagiri, Senior Director, Advanced Technologies, Cognito Therapeutics

About Cognito Therapeutics

Cognito Therapeutics is a clinical-stage neurotechnology company developing disease-modifying therapeutic approaches to treat neurodegenerative disorders. Its non-invasive neuromodulation platform was developed by MIT Professors and scientific founders Li-Huei Tsai and Ed Boyden. The Company’s lead therapy is currently in a pivotal study (HOPE) in Alzheimer’s Disease and was awarded FDA Breakthrough Device Designation. Cognito is based in Cambridge, MA. For more information, visit www.cognitotx.com. Follow us on Twitter at @cognitotx.

Contacts

Kimberly Ha

KKH Advisors

917-291-5744

[email protected]